Fecal transplantation for the treatment of recurrent Clostridium difficile infection

North American Journal of Medical Sciences

Volumn 5, Issue 6, 2013, Pages 339-343

  Karadsheh, Zeid ^a   Sule, Sachin ^b  

^a Brockton Hospital   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile infection, Fecal transplantation, Stool transplantation

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE ERADICATION; DISEASE SEVERITY; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INCIDENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

EID: 84879529377     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.114163     Document Type: Review

References (62)

1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Society for Healthcare Epidemiology of America. Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious disease society of America (IDSA). Infect Control Hosp Epidemiol 2010;5:431-55.
2. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts's hospitals: Clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219-27.
3. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NH. Increasing prevalence and severity of clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007;142:624-31.
4. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Eng J Med 2008;359:1932-40.
5. Gravel D, Gardam M, Taylor G, Miller M, Simor A, McGeer A, et al. Canadian nosocomial infection surveillance program. Infection control practices related to clostridium difficile infection in acute care hospitals in Canada. Am J Infect Control 2009;37:9-14.
6. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526-36.
7. Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Physician 2005;71:921-8.
8. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Athier S, et al. Emergence of fluoroquinolones as the predominant risk factor for clostridium difficile-associted diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60.
9. Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM, Killgore G, et al. Outbreak of clostridium difficile infection in a long-term facility: Association with galifloxacin use. Clin Infect Dis 2004;38:640-5.
10. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional out break of clostridium difficile-associated diarrhea with high morbidity and mortality. N Eng J Med 2005; 353:2442-9.
11. Bignardi GE. Risk factors for clostridium difficile infection. J Hosp Infect 1998;40:1-15.
12. Arango JI, Restrepo A, Schneider DL, Callander NS, Ochoa-Bayona JL, Restrepo MI, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantations for lymphoma and multiple myeloma. Bone Marrow Transplant 2006;37:517-21.
13. Carter GP, Rood JI, Lyras D. The role of toxin A and B in clostridium difficile-associated disease: Past and present prospectives. Gut Microbes 2010;1:58-64.
14. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-44.
15. Health Canada. C. difficile (clostridium difficile). (Accessed January 17, 2013, at http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/ diseases-maladies/cdiffi cle-eng.php).
16. Public Health Agency of Canada. Fact sheet-Clostridium difficle (C. difficile). (Accessed January 17, 2013, at http:// phac-aspc.gc.ca/id-mi/cdiff-eng.php).
17. Calfee DP. Clostridium difficle: A reemerging pathogen. Geriatrics 2008;63:10-21.
18. Bartlett JG. Narrative review: The new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-64.
19. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant Clostridium difficile: An underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363-72.
20. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care 2007;13:450-5.
21. Musher DM, Aslam S. Treatment of Clostridium difficile colitis in the critical care setting. Crit Care Clin 2008;24:279-91.
22. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, et al. Fulminant Clostridium difficile colitis: Patterns of care and predictors of mortality. Arch Surg 2009;144:433-9.
23. Gerding DN, Johnson S. Management of Clostridium difficile infection: Thinking inside and outside the box. Clin Infec Dis 2010;51:1306-13.
24. Imhoff A, Karpa K. Is there a future for probiotics in preventing Clostridium difficile-associated disease and treatment of recurrent episodes? Nutr Clin Pract 2009;24:15-32.
25. Rhode CL, Bartolini V, Jones N. The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea. Nutr Clin Pract 2009;24:33-40.
26. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trail of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.
27. Weiss K. Toxin-binding treatment for Clostridium difficile: A review including reports of studies with tolevamer. Int J Antimicrob Agents 2009;33:4-7.
28. Mattila E, Anttila VJ, Broas M, Marttila H, Poukka P, Kuusisto K, et al. A randomized, double-blind study comparing Clostridium difficle immune whey and metronidazole for recurrent Clostridium difficle-associated diarrhea: Efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 2008;40:702-8.
29. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009;15:1067-79.
30. Johnson S. Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes. J Infect 2009;58:403-10.
31. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficle disease. Am J Gastrenterol 2002;97:1769-75.
32. Surawicz CM. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2004;1:32-8.
33. Huebner ES, Surawicz CM. Treatment of recurrent Clostridium difficile diarrhea. Gastroenterol Hepatol (NY) 2006;2:203-8.
34. Reid G, Younes JA, Van der Mei HC, Gloor GB, Knight R, Busscher HJ. Microbiota restoration: Natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 2011;9:27-38.
35. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009;15:1554-80.
36. Bauer MP, van Dissel JT. Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents 2009;33:S51-6.
37. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31.
38. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut mirobiome. Nature 2011;473:174-80.
39. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary pattern with gut microbial enterotypes. Science 2011;334:105-8.
40. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011;9:279-90.
41. Palmer C, Bik EM, DiGiulio DB Relaman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol 2007;5:e177.
42. Marques TM, Wall R, Ross RP, Fitzgerald GF, Ryan CA, Stanton C. Programming infant gut mircobiota: Influence of dietary and environmental factores. Curr Opin Biotechnol 2010;21:149-56.
43. Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Dore J, et al. The Firmictus/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 2009;9:123.
44. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-8.
45. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet 1989;1:1156-60.
46. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854-9.
47. Landy J, AL-Hassi HO, McLaughlin SD, Walker AW, Ciclitira PJ, Nicholls RJ, et al. Review article: Fecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011;34:409-15.
48. Arkkila PE, Uusitalo-Seppala R, Lehtola L, Moilanan V, Ristikankare M, Mattila E. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Gastroenterology 2010;138 (Suppl 1):S5.
49. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of human microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010;44:354-60.
50. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: A case series of 12 patients. J Clin Gastroenterol 2010;44:562-6.
51. Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: Results and methodology. J Clin Gastroenterol 2010;44:567-70.
52. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010;8:471-3.
53. Garborg K, Waagsbo B, Stallemo A, Matre J, Sundoy A. Results of fecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhea. Scand J Infect Dis 2010;42:857-61.
54. Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: A proposed treatment protocol. Pediatrics 2010;126:e239-42.
55. Kelly C, de Leon L. Successful treatment of recurrent Clostridium difficile infection with donor stool administered at colonoscopy: A case series. Am J Gastroenterol 2010;105 (Suppl 1):S135.
56. Mellow M, Kanatzar A. Colonoscopic fecal bateriotherapy in the treatment of recurrent Clostridium difficile infection. Am J Gastroenterol 2010;105(Suppl 1):S135.
57. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplantation via retention enemas is effective for recurrent or refractory Clostridium difficile-associated diarrhea. Gastroenterology 2010;138:207-8.
58. Kelly C, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: Methodology and results. J Clin Gastroenterol 2012;46:145-9.
59. van Nood E, Vrieze A, Nieuwdrop M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15.
60. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriothrapy using fecal flora: Toying with human motions. J Clin Gastroenterol 2004;38:475-83.
61. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Fecal microbiota transplantation w orkgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;12:1044-9.
62. Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: "First-line" treatment for severe Clostridium difficile infection? J Clin Gastroenterol 2011;45:655-7.